The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure With Preserved Ejection Fraction: A Phase 2 Double-Blind Randomised Controlled Trial

Study Questions:

What are the efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in patients with New York Heart Association (NYHA) class II-III heart failure with preserved ejection fraction?